Table 2.

BRCA1/2 mutation status (whole cohorts) or HRD score (BRCA1/2 wild-type subset) and associations with response

A. BRCA1/2 mutation status
PrECOG 0105 Cohort (N = 66)
ResponderMutant number (% response)Nonmutant number (% response)OR (95% CI) Reference = nonmutantLogistic P
RCB 0/I = no524
RCB 0/I = yes15 (75%)22 (48%)3.27 (1.02–10.5)0.037
pCR = no1035
pCR = yes10 (50%)11 (24%)3.18 (1.05–9.63)0.040
Cisplatin Trials Cohort (N = 45)
ResponderMutant number (% response)Nonmutant number (% response)OR (95% CI) Reference = nonmutantLogistic P
RCB 0/I = no426
RCB 0/I = yes3 (42.9%)12 (31.6%)1.62 (0.31–8.43)0.57
pCR = no533
pCR = yes2 (28.6%)5 (13.2%)2.64 (0.40–17.5)0.33
B. HRD Score ≥42 (high vs. low), subset of BRCA1/2 wild-type tumors
PrECOG 0105 Cohort (N = 46)
ResponderHRD high number (% response)HRD low number (% response)OR (95% CI) Reference = low HRD scoreLogistic P
RCB 0/I = no1113
RCB 0/I = yes16 (59%)6 (32%)3.15 (0.92–10.8)0.062
pCR = no1817
pCR = yes9 (33%)2 (11%)4.25 (0.80–22.6)0.063
Cisplatin Trials Cohort (N = 38)
ResponderHRD high number (% response)HRD low number (% response)OR (95% CI) Reference = low HRD scoreLogistic P
RCB 0/I = no917
RCB 0/I = yes10 (52.6%)2 (10.5%)9.44 (1.69–52.7)0.0039
pCR = no1419
pCR = yes5 (26.3%)0 (0%)14.79 (1.49–201)0.018